202 related articles for article (PubMed ID: 19305985)
1. Individualised dosing of amikacin in neonates: a pharmacokinetic/pharmacodynamic analysis.
Sherwin CM; Svahn S; Van der Linden A; Broadbent RS; Medlicott NJ; Reith DM
Eur J Clin Pharmacol; 2009 Jul; 65(7):705-13. PubMed ID: 19305985
[TBL] [Abstract][Full Text] [Related]
2. Prospective Evaluation of a Model-Based Dosing Regimen for Amikacin in Preterm and Term Neonates in Clinical Practice.
Smits A; De Cock RF; Allegaert K; Vanhaesebrouck S; Danhof M; Knibbe CA
Antimicrob Agents Chemother; 2015 Oct; 59(10):6344-51. PubMed ID: 26248375
[TBL] [Abstract][Full Text] [Related]
3. The efficacy and toxicity of two dosing-regimens of amikacin in neonates with sepsis.
Abdel-Hady E; El Hamamsy M; Hedaya M; Awad H
J Clin Pharm Ther; 2011 Feb; 36(1):45-52. PubMed ID: 21198719
[TBL] [Abstract][Full Text] [Related]
4. Maturation of the glomerular filtration rate in neonates, as reflected by amikacin clearance.
De Cock RF; Allegaert K; Schreuder MF; Sherwin CM; de Hoog M; van den Anker JN; Danhof M; Knibbe CA
Clin Pharmacokinet; 2012 Feb; 51(2):105-17. PubMed ID: 22229883
[TBL] [Abstract][Full Text] [Related]
5. Amikacin in neonates: dosing recommendations should be based on both pharmacokinetics and dynamics.
Allegaert K; Sherwin CM
Singapore Med J; 2010 Jan; 51(1):88-9. PubMed ID: 20200782
[No Abstract] [Full Text] [Related]
6. Individualising netilmicin dosing in neonates.
Sherwin CM; Broadbent RS; Medlicott NJ; Reith DM
Eur J Clin Pharmacol; 2008 Dec; 64(12):1201-8. PubMed ID: 18685839
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of a new dosage regimen of amikacin based on pharmacokinetic parameters of Korean neonates.
An SH; Kim JY; Gwak HS
Am J Health Syst Pharm; 2014 Jan; 71(2):122-7. PubMed ID: 24375604
[TBL] [Abstract][Full Text] [Related]
8. Evaluating renal function and age as predictors of amikacin clearance in neonates: model-based analysis and optimal dosing strategies.
Illamola SM; Colom H; van Hasselt JG
Br J Clin Pharmacol; 2016 Sep; 82(3):793-805. PubMed ID: 27198625
[TBL] [Abstract][Full Text] [Related]
9. A gentamicin pharmacokinetic population model and once-daily dosing algorithm for neonates.
DiCenzo R; Forrest A; Slish JC; Cole C; Guillet R
Pharmacotherapy; 2003 May; 23(5):585-91. PubMed ID: 12741432
[TBL] [Abstract][Full Text] [Related]
10. Determination of Optimal Amikacin Dosing Regimens for Pediatric Patients With Burn Wound Sepsis.
Yu T; Stockmann C; Healy DP; Olson J; Wead S; Neely AN; Kagan RJ; Spigarelli MG; Sherwin CM
J Burn Care Res; 2015; 36(4):e244-52. PubMed ID: 25185930
[TBL] [Abstract][Full Text] [Related]
11. A Population and Developmental Pharmacokinetic Analysis To Evaluate and Optimize Cefotaxime Dosing Regimen in Neonates and Young Infants.
Leroux S; Roué JM; Gouyon JB; Biran V; Zheng H; Zhao W; Jacqz-Aigrain E
Antimicrob Agents Chemother; 2016 Nov; 60(11):6626-6634. PubMed ID: 27572399
[TBL] [Abstract][Full Text] [Related]
12. Amikacin Pharmacokinetics To Optimize Dosing in Neonates with Perinatal Asphyxia Treated with Hypothermia.
Cristea S; Smits A; Kulo A; Knibbe CAJ; van Weissenbruch M; Krekels EHJ; Allegaert K
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28993332
[TBL] [Abstract][Full Text] [Related]
13. Short versus long infusion of meropenem in very-low-birth-weight neonates.
Padari H; Metsvaht T; Kõrgvee LT; Germovsek E; Ilmoja ML; Kipper K; Herodes K; Standing JF; Oselin K; Lutsar I
Antimicrob Agents Chemother; 2012 Sep; 56(9):4760-4. PubMed ID: 22733063
[TBL] [Abstract][Full Text] [Related]
14. Nonparametric population pharmacokinetic analysis of amikacin in neonates, infants, and children.
Tréluyer JM; Merlé Y; Tonnelier S; Rey E; Pons G
Antimicrob Agents Chemother; 2002 May; 46(5):1381-7. PubMed ID: 11959572
[TBL] [Abstract][Full Text] [Related]
15. Extended-interval Dosing of Gentamicin in Premature Neonates Born at <32 Weeks' Gestation and >7 Days of age.
Sundaram A; Alshaikh B; Dersch-Mills D; Dobry J; Akierman AR; Yusuf K
Clin Ther; 2017 Jun; 39(6):1233-1241. PubMed ID: 28579209
[TBL] [Abstract][Full Text] [Related]
16. Once-a-day individualized amikacin dosing for suspected infection at birth based on population pharmacokinetic models.
Labaune JM; Bleyzac N; Maire P; Jelliffe RW; Boutroy MJ; Aulagner G; Putet G
Biol Neonate; 2001 Aug; 80(2):142-7. PubMed ID: 11509814
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of vancomycin dosing regimens in preterm and term neonates using Monte Carlo simulations.
Mehrotra N; Tang L; Phelps SJ; Meibohm B
Pharmacotherapy; 2012 May; 32(5):408-19. PubMed ID: 22488303
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic variability of amikacin after once-daily and twice-daily dosing regimen in full-term neonates.
Vučićević K; Rakonjac Z; Miljković B; Janković B; Prostran M
J Pharmacol Sci; 2014; 124(2):138-43. PubMed ID: 24441865
[TBL] [Abstract][Full Text] [Related]
19. The amikacin research program: a stepwise approach to validate dosing regimens in neonates.
Smits A; Kulo A; van den Anker J; Allegaert K
Expert Opin Drug Metab Toxicol; 2017 Feb; 13(2):157-166. PubMed ID: 27623706
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetics of vancomycin in premature Malaysian neonates: identification of predictors for dosing determination.
Lo YL; van Hasselt JG; Heng SC; Lim CT; Lee TC; Charles BG
Antimicrob Agents Chemother; 2010 Jun; 54(6):2626-32. PubMed ID: 20385872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
